VYLUMA COMPLETES LAST PATIENT VISIT FOR PRIMARY ANALYSIS OF PIVOTAL PHASE III CHAMP STUDY EVALUATING NVK002 FOR THE TREATMENT OF MYOPIA PROGRESSION IN CHILDREN
Multi-center, international clinical study designed to assess the safety and efficacy of novel investigational low-dose atropine eye drops in children 3-17 years old with myopia
VYLUMA AND LABORATOIRES THÉA ENTER INTO LICENSING AGREEMENT FOR THE REGISTRATION AND COMMERCIALIZATION OF NVK002 IN CANADA, MEXICO, AND SELECT SOUTH AMERICAN COUNTRIES
Bridgewater, NJ, USA, June 14, 2022 – Vyluma, Inc. (“Vyluma”), a biopharmaceutical company developing multiple assets in the ophthalmic space for the treatment of refractive errors, and Laboratoires Théa (“Théa”) announced that they have recently entered into an...
NEVAKAR INJECTABLES SELLS SIX DEVELOPMENT-STAGE, READY-TO-USE INJECTABLE PRODUCT CANDIDATES TO ENDO VENTURES LIMITED
Bridgewater, NJ, May 2, 2022 – Nevakar Injectables Inc. (“Nevakar”), a wholly owned subsidiary of Nevakar, Inc., is a biopharmaceutical company developing multiple sterile injectable products for use in the critical and ambulatory care settings. Nevakar announced...
NEVAKAR INJECTABLES RECEIVES U.S. FDA APPROVAL OF READY-TO-USE EPHEDRINE INJECTION IN A PREFILLED SYRINGE
Bridgewater, NJ, USA, April 28, 2022 – Nevakar Injectables Inc. (“Nevakar”), a wholly owned subsidiary of Nevakar, Inc., is a biopharmaceutical company developing multiple sterile injectable products for use in the critical and ambulatory care settings, and announced...
Nevakar Injectables Announces the Launch of Ready-to-Use Ephedrine Injection Vials
Bridgewater, NJ, USA, March 28, 2022 – Nevakar Injectables Inc., a biopharmaceutical company developing multiple sterile injectable products for use in the critical and ambulatory care settings, announced today the launch of its ready-to-use Ephedrine Sulfate...
Nevakar Announces Closing of $12 Million Convertible Note and Extension of Interest- Only Period with Oxford Finance
Bridgewater, NJ, USA, March 9, 2022 – Nevakar Inc. (“Nevakar”), a biopharmaceutical company developing multiple assets in the ophthalmic and injectable areas, announced today that it has closed on $12 million in convertible notes with both existing and new investors....
Nevakar Announces Closing of $12 Million Convertible Note and Extension of Interest- Only Period with Oxford Finance
Bridgewater, NJ, USA, March 9, 2022 – Nevakar Inc. (“Nevakar”), a biopharmaceutical company developing multiple assets in the ophthalmic and injectable areas, announced today that it has closed on $12 million in convertible notes with both existing and new investors....
VYLUMA AND MYMYOPIA.COM SUPPORT 2021 WORLD SIGHT DAY TO RAISE AWARENESS OF VISION DISORDERS
Bridgewater, NJ (October 7, 2021) – Vyluma Inc. and MyMyopiaTM (MyMyopia.com) are excited to announce new tools and resources to support the International Agency for the Prevention of Blindness (IAPB) World Sight Day, a global event to draw attention to blindness and...
VYLUMA INC LAUNCHES WITH ROBUST OPHTHALMIC PORTFOLIO, LEADING WITH A PHARMACEUTICAL TREATMENT IN PHASE III FOR MYOPIA
Bridgewater, NJ (May 25, 2021) – Vyluma Inc. announces its establishment as a wholly owned subsidiary of Nevakar Inc., focusing on pharmaceutical ophthalmic solutions. The robust pipeline of novel therapies is led by NVK002, a pharmaceutical atropine eyedrop to slow...
NEVAKAR INC. ANNOUNCES FORMATION OF NEVAKAR INJECTABLES
Bridgewater, NJ (May 25, 2021) – Nevakar Inc. (“Nevakar”), a privately held biopharmaceutical company, today announces the establishment of Nevakar Injectables Inc., a newly formed company with an established portfolio of products focused on critical patient care,...
Industry Focus: A Look at Nevakar
By JASON J. NICHOLS, OD, MPH, PHD View the article | CLICK HERE Dr. Puri, please tell us about your company in terms of its history and direction...
NEVAKAR AND THÉA ENTER INTO LICENSING AGREEMENT FOR THE COMMERCIALIZATION OF NVK002 (ATROPINE FOR THE TREATMENT OF THE PROGRESSION OF MYOPIA IN CHILDREN) IN EUROPE
Bridgewater, NJ, USA and Clermont-Ferrand, France, January 28, 2021 – Nevakar Inc. (“Nevakar”), a biopharmaceutical company developing multiple assets in the ophthalmic and injectable areas, and Laboratoires Théa (“Théa”) announced today that they recently entered...
Nevakar Announces First Subject Dosed in its Phase 3 Clinical Trial of NVK002 for the Treatment of Myopia in Children
Bridgewater, NJ, USA and Clermont-Ferrand, France, January 28, 2021 – Nevakar Inc. (“Nevakar”), a biopharmaceutical company developing multiple assets in the ophthalmic and injectable areas, and Laboratoires Théa (“Théa”) announced today that they recently entered...
American Academy of ophthalmology leads global initiative to address worldwide myopia epidemic
SAN FRANCISCO – Nov. 11, 2020 – The number of Americans who are nearsighted has nearly doubled over the last 50 years to about 41.6 percent. This upward trend is evident in nearly every corner of the world, but nowhere near as dramatic as in East and Southeast Asia,...
FIRST PATIENT COMPLETES THREE YEAR ENROLLMENT IN NEVAKAR’S PHASE III CHAMP STUDY OF NVK002 EVALUATING LOW-DOSE ATROPINE OPHTHALMIC SOLUTION FOR THE TREATMENT OF MYOPIA IN CHILDREN
Bridgewater, NJ, November 9, 2020 – Nevakar Inc., a biopharmaceutical company developing multiple products in the ophthalmic and injectable areas, announced today that the first patient has completed three year enrollment in its Phase III CHAMP (Childhood Atropine for...
Nevakar Announces FDA Approval for Ephedrine Sulfate Injection as Ready-to-Use Vials
Bridgewater, NJ, October 22, 2020 – Nevakar Inc., a biopharmaceutical company developing multiple assets in the ophthalmic and injectable areas, announced today it received approval from the U.S. Food and Drug Administration (FDA) to market Ephedrine Sulfate Injection...
Nevakar and zhaoke ophthalmology enter into licensing agreement for nvk002 (atropine for the treatment of the progression of myopia in children)
Bridgewater, NJ (USA) and Hong Kong S.A.R., October 20, 2020 – Nevakar Inc. (“Nevakar”), a privately held, late-stage, biopharmaceutical company developing multiple innovative medications in the ophthalmic and hospital injectable areas, and Zhaoke (Hong Kong)...
American Society of Hospital Pharmacists Midyear (ASHP)
December 8, 2019 - December 12, 2019
MyMyopia™ Introduces Infographic for Easy Understanding of Myopia, its Impact, and Treatment Options
BRIDGEWATER, N.J., May 5, 2020 -- MyMyopia™ is a disease awareness effort that shares important information with parents and eye care professionals on the growing childhood myopia epidemic. It seeks to improve lifelong ocular health through education and has released...
Nevakar Completes $30 Million Financing to Advance Pipeline Products
Bridgewater, NJ, / Raleigh, NC, JUNE 18, 2019 – Nevakar Inc. ("Nevakar" or the "Company"), a specialty pharmaceutical company developing multiple assets in the ophthalmic and injectable areas, announced today that it recently entered into a $50 million product...
Nevakar Enters into $17.5 Million Product Financing Agreement with H.I.G. Capital Partners for Continued Development of Injectable Products
Bridgewater, NJ, OCTOBER 7, 2019 – Nevakar Inc., a specialty pharmaceutical company developing multiple assets in the ophthalmic and injectable areas, announced today that it has entered into a $17.5 million product financing agreement with an affiliate of H.I.G....
Nevakar completes enrollment for its phase iii champ study of nvk002
Bridgewater, NJ, SEPTEMBER 11, 2019 – Nevakar Inc., a privately-held, late-stage specialty pharmaceutical company dedicated to developing innovative ophthalmic products, announced today that it has completed enrollment for its Phase III CHAMP (Childhood Atropine for...
Nevakar Enters $50 Million Product Financing Agreement with NovaQuest Capital for Continued Development of Injectable Products
Bridgewater, NJ, / Raleigh, NC, JUNE 18, 2019 – Nevakar Inc. ("Nevakar" or the "Company"), a specialty pharmaceutical company developing multiple assets in the ophthalmic and injectable areas, announced today that it recently entered into a $50 million product...
Nevakar and Endo Enter into Exclusive Licensing Agreement for Multiple 505(b)(2) Injectable Products
Bridgewater, NJ, AUGUST 8, 2018 – Nevakar Inc., a specialty pharmaceutical company developing multiple assets in the ophthalmic and injectable areas, announced today that it recently entered into an exclusive licensing agreement with Endo International plc's (NASDAQ:...
Nevakar Announces First Subject Dosed in its Phase 3 Clinical Trial of NVK002 for the Treatment of Myopia in Children
BRIDGEWATER, N.J., Nov. 21, 2017 -- Nevakar LLC, a privately-held specialty pharmaceutical company developing innovative therapies within the injectable and ophthalmic space, today announced that the first subject has been dosed in a Phase 3 clinical trial of NVK002,...